铂类敏感的卵巢癌治疗:Ipafricept的骨毒性超过潜在疗效

2019-08-27 Allan MedSci原创

Ipafricept是一种潜在的铂类敏感性卵巢癌治疗药物,但早期临床试验显示其具有骨毒性,将不会被进一步研究。Ipafricept阻断Wnt通路的信号传导,Wnt通路是上皮性卵巢癌的一个重要的肿瘤学驱动因素。

Ipafricept是一种潜在的铂类敏感性卵巢癌治疗药物,但早期临床试验显示其具有骨毒性,将不会被进一步研究。Ipafricept阻断Wnt通路的信号传导,Wnt通路是上皮性卵巢癌的一个重要的肿瘤学驱动因素。该研究的作者之一Mantia-Smaldone说:“Wnt途径被认为与卵巢癌中的干细胞途径有关。这种疗法是想论证Ipafricept能否攻击肿瘤干细胞,以预防疾病复发并导致更长的生存期

卵巢癌是发源自女性卵巢的癌症,会产生会入侵以及转移到其他部位的异常细胞。卵巢癌初期症状不明显,随病情进展,才会出现许多癌症的典型症状,包括胀气、腹胀、骨盆痛等。癌症较容易扩散到腹膜、淋巴结、肺脏、肝脏等部位。


原始出处:

http://www.firstwordpharma.com/node/1661877#axzz5xlMZFkAB

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1737616, encodeId=757f1e37616dd, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Thu Oct 24 01:18:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568601, encodeId=f7ad1568601c3, content=<a href='/topic/show?id=139f9658680' target=_blank style='color:#2F92EE;'>#铂类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96586, encryptionId=139f9658680, topicName=铂类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eed15401054, createdName=fengxx, createdTime=Thu Aug 29 06:18:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032262, encodeId=3a76103226290, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Aug 27 18:18:00 CST 2019, time=2019-08-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1737616, encodeId=757f1e37616dd, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Thu Oct 24 01:18:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568601, encodeId=f7ad1568601c3, content=<a href='/topic/show?id=139f9658680' target=_blank style='color:#2F92EE;'>#铂类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96586, encryptionId=139f9658680, topicName=铂类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eed15401054, createdName=fengxx, createdTime=Thu Aug 29 06:18:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032262, encodeId=3a76103226290, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Aug 27 18:18:00 CST 2019, time=2019-08-27, status=1, ipAttribution=)]
    2019-08-29 fengxx
  3. [GetPortalCommentsPageByObjectIdResponse(id=1737616, encodeId=757f1e37616dd, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Thu Oct 24 01:18:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568601, encodeId=f7ad1568601c3, content=<a href='/topic/show?id=139f9658680' target=_blank style='color:#2F92EE;'>#铂类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96586, encryptionId=139f9658680, topicName=铂类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eed15401054, createdName=fengxx, createdTime=Thu Aug 29 06:18:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032262, encodeId=3a76103226290, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Aug 27 18:18:00 CST 2019, time=2019-08-27, status=1, ipAttribution=)]
    2019-08-27 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

CLIN CANCER RES:抗肿瘤干细胞药物Ipafricept治疗晚期实体瘤患者

Wnt信号与肿瘤细胞去分化及肿瘤干细胞功能关系密切。Ipafricept(OMP-54F28)是一种重组融合蛋白,将人frizzled 8受体胞外部分与可跟Wnt配体结合的IgG1 Fc片段融合。CLIN CANCER RES近期发表了一篇文章,评估Ipafricept在实体瘤患者中的疗效。